Hepatitis C: An update on the silent epidemic

Journal of Clinical Gastroenterology

Volumn 30, Issue 2, 2000, Pages 125-143

  Sarbah, Steedman A ^a   Younossi, Zobair M ^b  

^a METROHEALTH MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Clinical manifestations; Epidemiology; Extrahepatic disease; Hepatitis C; Therapy

Indexed keywords

ALCOHOL; ALPHA INTERFERON; ALPHAN1 INTERFERON; AMANTADINE; ANTIOXIDANT; ANTIVIRUS AGENT; CONSENSUS INTERFERON; CRYOGLOBULIN; IMMUNOMODULATING AGENT; IRON; PENTOXIFYLLINE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIMANTADINE; THYMOSIN ALPHA1; VIRUS RNA;

ALOPECIA; ARTHRALGIA; ASTHENIA; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DISEASE COURSE; ELECTROIMMUNOASSAY; ENDOCRINE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; EPISTAXIS; FLU LIKE SYNDROME; GLOMERULOPATHY; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOPATHOLOGY; INSOMNIA; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN MANIFESTATION; UNITED STATES; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; RISK FACTORS;

EID: 0034060956     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200003000-00005     Document Type: Review

References (176)

1. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
2. Kuo G, Choo Q-L, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B antibodies. Science 1989;244: 362-4.
3. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975;292:767-70.
4. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327: 1899-905.
5. Younossi ZM. Chronic hepatitis C: a clinical overview. Cleve Clin J Med 1997;64:259-68.
6. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
7. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993;88:240-3.
8. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. Hepatology 1997;26:485-90.
9. DiBisceglie AM. Hepatitis C. Lancet 1998;351:351-5.
10. Hsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-801.
11. Davis GL, Albright JE, Cook S, Rosenburg D. Projecting the future healthcare burden from hepatitis C in the United States [abstract]. Hepatology 1998;28:390A.
12. Bader T. New worry and hope for hepatitis C carriers. Practical Hepatitis Update 1999;1:1-6.
13. Seef LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-11.
14. Silini E, Bottelli R, Asti M, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 1996;111:199-205.
15. Anonymous. Recommendations for the prevention and control of Hepatitis C virus (HCV) infection and HCV-related chronic liver disease. MMWK 1998;47:1-39.
16. Younossi ZM, Hepatitis C. Update: implications of the blood transfusion "look back." Cleve Clin J Med 1988;65:412-20.
17. Makris M, Garson JA, Ring CJ, Tuke PW, Tedder RS, Preston FE. Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. Blood 1993;81:1898-902.
18. Troisi CL, Hollinger FB, Hoots WK, et al. A multi center study of viral hepatitis in a United States hemophilic population. Blood 1993;81:412-8.
19. Schreiber GB, Busch MP, Kleinman SH, Korelitz JT. The risk of transfusion-transmitted viral infection. N Engl J Med 1996;334:1685-90.
20. Garfein RS, Vlahov D, Galai N, Donerty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency and human T-lymphotropic viruses. Am J Pub Health 1996;86:655-61.
21. Hon CH, Chen WV, Kao JH, Chen DS. Intrafamilial transmission of hepatitis C virus in hemodialysis patients. J Med Virol 1995;45:381-5.
22. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis associated diseases in the United States 1995. ASAIO J 1998;44:98-107.
23. Sarbah SA, Mullen K. Risk factors for viral hepatitis B and C help identify disease. Practical Gastroenterol 1998;22:10-26.
24. Caramello C, Navas S, Alberola ML. Evidence against transmission of hepatitis C virus through hemodialysis ultrafiltrate and peritoneal fluid. Nephron 1994;66:470-3.
25. Everhart JE, Di Bisceglie AM, Murray LM, et al. Risk for non-A, non-B (type C) hepatitis through sexual and household contact with chronic carriers. Ann Intern Med 1990;112:544-55.
26. Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatology 1997;26(suppl 1):665-705.
27. Melbye M, Biggar RT, Wantzin P, Krogsgaard K. Sexual transmission of hepatitis C virus: Cohort study (1981-1989) among European homosexual men. BMJ 1990;301:210-2.
28. Thomas DL, Zenilman JM, Alter HJ. Sexual transmission of hepatitis C virus among patients attending STD clinics in Baltimore. J Infect Dis 1995; 171:768-75.
29. Fried MW, Shindo M, Fon T-L, Fox PC, Hoofnagle JH, Di Bisceglie AM. Absence of hepatitis C viral RNA from saliva and semen of patients with chronic hepatitis C. Gastroenterology 1992;102:1306-8.
30. Soto B, Rodrigo L, Garcia-Bengoechea M, Sanchez-Quijano A. Heterosexual transmission of hepatitis C virus and the possible role of co-existent human immunodeficiency virus infection in the index case: a multi center study of 423 parings. J Intern Med 1994;236:515-9.
31. Shev S, Widell A, Bergstrum T, Hermodsson S, Lindholm A. Herpes simplex virus-2 may increase susceptibility of the transmission of hepatitis C. Sex Transm Dis 1995;22:210-6.
32. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mother to infants. N Engl J Med 1994;330:744-50.
33. Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lancet 1995;345:289-91.
34. Granovsky MO, Minkoff HL, Tess BH, et al. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics 1998;102:355-9.
35. Müller R. The natural history of hepatitis C: clinical experiences. J Hepatol 1996;24(suppl 2):52-4.
36. Lin HH, Kao JH, Hsu HY, et al. Possible role of high-titer maternal viremia in perinatal transmission of hepatitis C virus. J Infect Dis 1994;169:638-41.
37. Manzini P, Saracco G, Cerchier A, et al. Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother's anti-hepatitis C immunoblotting pattern. Hepatology 1995;21:328-32.
38. Lin HH, Kao JH, Hsu HY, et al. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr 1995;126L:589-91.
39. Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C sero-conversion after occupational exposures in health care workers. Am J Infect Control 1995; 23:273-7.
40. Lanphear BP, Linnemann CC Jr, Cannon CG, et al. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol 1994;15:745-50.
41. Polish LB, Tong MJ, Co RL, Coleman PJ, Alter MJ. Risk factors for hepatitis C virus infection among health care personnel in a community hospital. Am J Infect Control 1993;21:196-200.
42. Thomas DL, Gruninger SE, Siew C, Joy ED, Quinn TC. Occupational risk of hepatitis C infection among general dentists and oral surgeons in North America. Am J Med 1996;100:41-5.
43. Mitsui T, Iwano K, Masuko K, Yamazaki C, Okamoto H. Hepatitis C virus infection in medical personnel after needle-stick accident Hepatology 1992; 16:1109-14.
44. Esteban JI, Gomez J, Martell M, et al. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996;334:555-60.
45. Younossi ZM, McHutchison JG. Serological tests for HCV infection. Hepatitis Rev 1996;2:161-73.
46. de Medina M, Schiff ER. Hepatitis C: diagnostic assays. Semin Liver Dis 1995;15:33-40.
47. McFarlane IG, Smith HM, Johnson PJ, et al. Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false positive results? Lancet 1990;335:754-7.
48. Uyttendaele S, Claeys H, Mertens W. et al. Evaluation of third generation screening and confirmatory assays for HCV antibodies. Vox Sang 1994;66: 122-9.
49. Zaaijer HL, Vrielink H, Van Exel-Oehlers P, et al. Confirmation of hepatitis C infection: a comparison of five immunoblot assays. Transfusion 1994; 34:603-7.
50. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98-104.
51. Lok ASF, Chien D, Choo QL, et al. Antibody response to core, envelope and non-structural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993;18:497-502.
52. Zaaijer HL, Cuypers HTM, Reesink HW, et al. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993;341:722-4.
53. Gretch DR, dela Rosa D, Caithers RL Jr, Wilson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlation and clinical implications. Ann Intern Med 1995;123:321-9.
54. Urdea MS. Branched DNA signal amplification. Biotechnology 1994;12: 926-7.
55. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26(suppl 1):15-20.
56. Barrera JM, Bruguera M, Guadalupe-Ercilla M, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995;21:639-44.
57. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995;15:70-81.
58. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19: 1513-20.
59. Perrillo RP. The role of liver biopsy in Hepatitis C. Hepatology 1997;26 (suppl 1):57-61.
60. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
61. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 1997;349(9055):825-32.
62. Albloushi SS, Murray FE, Callagy G, Courtney MG, O'Keane JC, Kay E. Changes in liver histopathology in women infected with hepatitis C through contaminated anti-D immunoglobulin injections in Ireland. Eur J Gastroenterol Hepatol 1998;10:69-73.
63. Shindo M, Arai K, Sokawa Y, Okuno T. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995;22:418-25.
64. Puoti C, Margrini A, Stati T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997;26:1393-8.
65. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-72.
66. National Institutes of Health Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997;26(suppl 1):2-10.
67. Gordon SC. Extra hepatic manifestations of hepatitis C. Dig Dis 1996;14: 157-68.
68. Hadziyannis SJ. Non hepatic manifestations and combined diseases in HCV infection. Dig Dis Sci 1996;41(suppl 12):63-74.
69. Elder GH. Porphyria cutanea tarda [review], Semin Liver Dis 1998;18:67-75.
70. Kushner JP, Steinmuller P, Lee GR. The role of iron in the pathogenesis of porphyria cutanea tarda. J Clin Invest 1975;56:661-7.
71. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998;27:1661-9.
72. Herrero C, Vincente A, Bruguera M, et al. Is hepatitis C a trigger for porphyria cutanea tarda? Lancet 1993;341:788-9.
73. Grossman ME, Bickers DR, Poh-Fitzpatrick MB, et al. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. Am J Med 1979:67;277-86.
74. Rocci E, Gibertini P, Cassanelli M, et al. Iron removal therapy in porphyria cutanea tarda: phlebotomy versus slow subcutaneous desferrioxamine infusion. Br J Dermatol 1986;114:621-9.
75. Ashton RE, Hawk JML, Magnus IA. Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. Br J Dermatol 1981;111:609-13.
76. Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-α therapy in a case of chronic hepatitis C. Dig Dis Sci 1998;43:529-33.
77. Rich JD, Mylonakis E, Nossa R, Chapnick RM. Highly active antiretroviral therapy leading to resolution of porphyria cutanea tarda in a patient with AIDS and hepatitis C. Dig Dis Sci 1999;44:1034-7.
78. Pakula AS, Garden JM, Roth SI. Cryoglobulinemia and cutaneous leukocytoclastic vasculitis associated with hepatitis C virus infection. J Am Acad Dermatol 1993;28:850-3.
79. Daoud MS, Gibson LE, Daoud S, el-Azhary RA. Chronic hepatitis C and skin diseases: a review. Mayo Clin Proc 1995;70:559-64.
80. Gandolfo S, Carbone M, Carrozzo M, Gallo V. Oral lichen planus and hepatitis C virus (HCV) infection: is there a relationship? A report of 10 cases. J Oral Pathol Med 1994;23:119-22.
81. Kanazawa K, Yaoita H, Tsuda F, Okamoto H. Hepatitis C virus infection in patients with urticaria. J Am Acad Dermatol 1996;35(2 pt 1):195-8.
82. Reichel M, Mauro TM. Urticaria and hepatitis C. Lancet 1990;336:822-33.
83. Czaja AJ. Extrahepatic immunologic features of chronic viral hepatitis. Dig Dis 1997;15:125-44.
84. Pawlotsky M, Yahia MB, Andre C, Voisin M-C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994;19:841-8.
85. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775-88.
86. Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106:1291-300.
87. Pascual M, Perrin L, Giostra E, Schifferli JA. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 1990;162:569-70.
88. Lunel F, Musset L. Hepatitis C infection and cryoglobulinemia. J Hepatol 1998:29;848-55.
89. Manzin A, Solforosi L, Candela M, et al. Hepatitis C virus infection and mixed cryoglobulinemia: assessment of HCV RNA copy numbers in supernatant, cryoprecipitate and non-liver cells. J Viral Hepatol 1996;6:285-92.
90. Roccatello D, Morsica G, Picciotti G, et al. Impaired hepatosplenic elimination of circulatory cryoglobulins in patients with essential mixed cryoglobulinemia and hepatitis C virus (HCV) infection. Clin Exp Immunol 1997;110:9-14.
91. Lunel F, Musset L. Hepatitis C infection and cryoglobulinemia. Viral Hepatitis Rev 1996;2:111-24.
92. Frangeul L, Musset L, Cresta P, Cacoub P, Huraux J-M, Lunel F. Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia. J Hepatol 1996;25:427-32.
93. Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980;69:287-308.
94. Geltner D. Therapeutic approaches in mixed cryoglobulinemia. Springer Semin Immunopathol 1988;10:103-13.
95. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-6.
96. Dammacco F, Sansonno D, Han JH, et al. Natural interferon alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long term, randomized, controlled study. Blood 1994; 84:3336-43.
97. Zignego AL, Ferri C, Giannini C, et al. HCV infection in B-cell non-Hodgkin's lymphoma. J Hepatol 1995;23(suppl 1):77.
98. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995;21:613-9.
99. Verbaan H, Carlson J, Eriksson S, et al. Extrahepatic manifestations of chronic hepatitis C infection and the inter relationship between primary Sjögren's syndrome and hepatitis C in Swedish patients. J Intern Med 1999;245:127-32.
100. Durand JM, Lefevre P, Telle H, Kaplanski G, Quiles N, Soubeyrand J. Thrombocytopenic purpura and hepatitis C virus infection [letter]. Haematologica 1993;78:135.
101. Cacoub P, Lunel-Fabiani F, Du LT. Polyarteritis nodosa and hepatitis C virus infection. Ann Intern Med 1992;116:605-6.
102. Lacaille F, Zylberberg H, Hagege H, et al. Hepatitis C associated with Guillain-Barre syndrome. Liver 1998;18:49-51.
103. Eddy S, Wim R, Peter VE, Tanja R, Jan T, Werner VS. Myasthenia gravis: another autoimmune disease associated with hepatitis C virus infection. Dig Dis Sci 1999;44:186-9.
104. Buskila D, Shnaider A, Neumann L, Zilberman D, Hilzenrat N, Sikuler E. Fibromyalgia in hepatitis C virus infection. Another infectious disease relationship. Arch Intern Med 1997;157:2497-500.
105. Ferri C, La Civita L, Fazzi P, et al. Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. Br J Rheumatol 1997; 36:360-5.
106. Johnson RJ, Wilson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int 1994;46:1255-63.
107. Yamabe H, Johnson RJ, Gretch DR, et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 1995;6:220-3.
108. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-70.
109. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 1999;106:347-54.
110. De Vecchi A, Montagnino G, Pozzi C, Tarantino A, Locatelli F, Ponticelli C. Intravenous methylprednisolone pulse therapy in essential mixed cryoglobulinemia nephropathy. Clin Nephrol 1983;19:221-7.
111. Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997;26:206-10.
112. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol 1995;22:364-9.
113. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatalogy 1999;29:328-3.
114. Mangia A, Schiavone G, Lezzi G, et al. HCV and diabetes mellitus: evidence for a negative association. Am J Gastroenterol 1998;93:2363-7.
115. Hadziyannis S, Karamanos B. Diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:604-5.
116. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-8.
117. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258-67.
118. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 3997;26(suppl 1):71-7.
119. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
120. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C: effect of dose increment and duration of treatment on response rates. Results of the first multicenter Australian trial. J Hepatol 1995;23:487-96.
121. Poynard R, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, Non-B hepatitis. N Engl J Med 1995;332:1457-62.
122. Lee WM. Therapy of hepatitis C: interferon alfa-2a trials. Hepatology 1997; 26(suppl 1):89-95.
123. Myron MJ, Reddy R, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology 1997;26:747-54.
124. Healthcote EJ, Keeffe EB, Lee SS, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136-43.
125. Farrell GC. Therapy of hepatitis C: interferon alfa-n1 trials. Hepatology 1997;26(suppl 1):96-100.
126. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C Hepatology 1997;26(suppl 1):122-7.
127. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26(suppl 1):112-21.
128. Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of interferon alfa-2b in patients with hepatitis C: a randomized multicenter trial. Hepatology 1996;24:1034-40.
129. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
130. Shiffman ML. Use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis 1999:19(suppl 1):25-33.
131. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C patients with a previous non-response or non-sustained response to interferon. J Med Virol 1995;46:43-7.
132. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: meta-analysis of individual patient data from European centers. J Hepatol 1997;26:961-6.
133. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
134. Fernandez H, Banks G, Smith R. Ribavirin: a clinical overview. Eur J Epidemiol 1986;2:1-14.
135. Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alpha-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998;46:563-70.
136. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999:19(suppl 1):17-24.
137. Poynard T, McHutchison J, Goodman Z, Ling M-H, Albrecht J. Is an "A la carte" combination interferon-alfa2b plus ribavirin regimen possible for the first line treatment in patients with hepatitis C. Hepatology 2000;31:211-8.
138. Bonkovsky HL. Therapy of hepatitis C: other options. Hepatology 1997; 26(suppl 1):143-51.
139. Maynard M, Choistermon S, Baud M, et al. Interferon (IFN) therapy combined with nonsteroid anti-inflammatory drugs (AINS) does not induce a significant increase of 2′5′oligoadenylate synthetase (2′5′ AS) activity in patients with chronic hepatitis C [abstract]. Hepatology 1996;24:403.
140. Takono S, Ito Y, Yokosuka O, et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994;20:558-64.
141. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurement of iron status in patients with chronic hepatitis. Gastroenterology 1992;102: 2108-13.
142. Weinburg E, Wienburg G. The role of iron in infection. Curr Opin Infect Dis 1995;8:164-69.
143. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gasteroenterol 1994;89:986-8.
144. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997;42:1681-7.
145. Younossi ZM, Perrillo RP. The roles of amantadine, Rimantadine, ursode-oxycholic acid and NSAIDS, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Semin Liver Dis 1999;19(suppl 1):95-102.
146. Brillanti S, Foli M, Gramantieri L, Di Tomaso M, Masci C, Bolondi L. Triple antiviral therapy for chronic hepatitis C in interferon alfa non-responders: a pilot randomized controlled study [abstract]. Hepatology 1997;26:367.
147. Sherman KE, Sjögren M, Creager RL, et al. Combination therapy with thymosin alpha 1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 1998;27:1128-35.
148. Beloqui O, Prieto J, Suàrez M, et al. N-acetyl cysteine enhances the response to interferon-α in chronic hepatitis C: a pilot study. J Interferon Res 1993;13:279-82.
149. Venkataramani A, Houglum K, Lyche K, Chojkier M. Oxidative stress mediates activation of stellate cells and fibrogenesis in patients with chronic hepatitis C: beneficial effects of d-α tocopherol [abstract]. Hepatology 1996;24:150.
150. Desmoulier A, Xu G, Costa AM, et al. Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells. J Hepatol 1999;30:621-31.
151. Lebovics E, Casellas A, Dworkin B, Chan S, Rosenthal WAS. Pentoxifylline enhances response to chronic hepatitis C to interferon α-2b: a doubleblind randomized controlled trial [abstract]. Hepatology 1996;24:402.
152. Davis GL, Nelson DR, Reyes GR. Future options for the management of hepatitis C. Semin Liver Dis 1999;19(suppl 1):103-12.
153. Baba M, Iishi H, Tatsuta M. In vivo electroporetic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats. Int J Cancer 2000;85:260-6.
154. Pardo M, Castillo I, Oliva H, et al. Pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. Hepatology 1997;26:1318-21.
155. Lemon S, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997;336:196-204.
156. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 1994;91:1294-8.
157. Inchauspé G. DNA vaccine strategies for hepatitis. Can J Hepatol 1999; 30:339-46.
158. Schiff ER. Hepatitis C and alcohol. Hepatology 1997;26(suppl 1):39-12.
159. Cromie SL, Jenkins PJ, Bowden DS, Dudley FJ. Chronic hepatitis C: effect of alcohol on hepatitic activity and viral titre. J Hepatol 1996;25:821-6.
160. Pessione F, Dregos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:1717-22.
161. Oshita M, Hayashk N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels amongst alcoholic patients with chronic hepatitis C. Hepatology 1994;20:1115-20.
162. Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 1996;91:1367-73.
163. Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999;29:1220-6.
164. Rosen HR, Gretch DR, Oehlke M, et al. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998;65:1178-82.
165. Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27:1403-7.
166. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28(3):823-30.
167. Bona MD, Rupolo G, Ponton P, et al. The effect of recurrence of HCV infection on life and liver transplantation. Transpl Int 1998;11(suppl 1): 475-9.
168. Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999;117:149-53.
169. Platz KP, Mueller AR, Berg T, et al. Searching for the optimal management of hepatitis C patients after liver transplantation. Transpl Int 1998;11(suppl 1):209-11.
170. Casavilla FA, Rakela J, Kapur S, et al. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg 1998;4:448-54.
171. Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998;66:471-6.
172. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10 year follow-up. Hepatology 1999;29:1893-9.
173. Soriano V, Rodríguez-Rosado R, García-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS 1999;13:539-46.
174. Soriano V, García-Samaniego J, Bravo R, et al. Interferon α for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:585-91.
175. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. N Engl Organ Bank Hepatitis C Study Group Kidney Int 1998;53:1374-81.
176. Dussol B, Berthezene P, Brunet P, Roubicek C, Berland Y. Hepatitis C virus infection among chronic dialysis patients in the south of France: a collaborative study. Am J Kidney Dis 1995;25:399-404.